CASP1 and type 2 diabetes mellitus: There are three promising therapeutic agents for T2DM that target IL-1β and Caspase-1: (1) IL-1 receptor antagonist Anakinra (208), (2) human anti-IL-1β monoclonal antibody Canakinumab (209), (3) Caspase-1 inhibitor Pralnacasan.